These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 30253682)

  • 1. Risk of Nephrotoxicity Associated With Nonrenally Adjusted Intravenous Polymyxin B Compared to Traditional Dosing.
    Maniara BP; Healy LE; Doan TL
    J Pharm Pract; 2020 Jun; 33(3):287-292. PubMed ID: 30253682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nephrotoxicity Associated with Intravenous Polymyxin B Once- versus Twice-Daily Dosing Regimen.
    Okoduwa A; Ahmed N; Guo Y; Scipione MR; Papadopoulos J; Eiras DP; Dubrovskaya Y
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29844039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of Acute Kidney Injury in Intermittent Versus Continuous Infusion of Polymyxin B in Hospitalized Patients.
    Alvarado Reyes Y; Cruz R; Gonzalez J; Perez Y; Wolowich WR
    Ann Pharmacother; 2019 Sep; 53(9):886-893. PubMed ID: 30971094
    [No Abstract]   [Full Text] [Related]  

  • 4. Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy.
    Kubin CJ; Ellman TM; Phadke V; Haynes LJ; Calfee DP; Yin MT
    J Infect; 2012 Jul; 65(1):80-7. PubMed ID: 22326553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of polymyxin B-induced acute kidney injury with a non adjusted dose versus adjusted dose based on renal function.
    Zheng G; Cai J; Zhou S; Du N; Bai H; He J; Bian X
    Per Med; 2022 Jul; 19(4):307-314. PubMed ID: 35762314
    [No Abstract]   [Full Text] [Related]  

  • 6. A Comparison of Adjusted Versus Unadjusted Doses of Polymyxin B Based on Renal Function and Incidence of Acute Kidney Injury.
    Peyko V; Cohen H
    J Pharm Pract; 2020 Jun; 33(3):255-261. PubMed ID: 30189762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium.
    Tuon FF; Rigatto MH; Lopes CK; Kamei LK; Rocha JL; Zavascki AP
    Int J Antimicrob Agents; 2014 Apr; 43(4):349-52. PubMed ID: 24439066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: a multicentre prospective cohort study.
    Rigatto MH; Behle TF; Falci DR; Freitas T; Lopes NT; Nunes M; Costa LW; Zavascki AP
    J Antimicrob Chemother; 2015 May; 70(5):1552-7. PubMed ID: 25604744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for polymyxin B-associated acute kidney injury.
    Chang K; Wang H; Zhao J; Yang X; Wu B; Sun W; Huang M; Cheng Z; Chen H; Song Y; Chen P; Chen X; Gan X; Ma W; Xing L; Wang Y; Cao B
    Int J Infect Dis; 2022 Apr; 117():37-44. PubMed ID: 35108608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and risk factors for acute kidney injury associated with parenteral polymyxin B use.
    Mendes CA; Cordeiro JA; Burdmann EA
    Ann Pharmacother; 2009 Dec; 43(12):1948-55. PubMed ID: 19887593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Risk factors for acute kidney injury in patients treated with polymyxin B experience from 139 cases at a tertiary university hospital in Colombia].
    Osorio J; Barreto J; Samboni CF; Cándelo LA; Álvarez LC; Benavidez S; Téllez RP; Santofimio D; Ramos JA; Gómez CA
    Rev Chilena Infectol; 2017 Feb; 34(1):7-13. PubMed ID: 28394975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymyxin-B and vancomycin-associated acute kidney injury in critically ill patients.
    Soares DS; Reis ADF; Silva Junior GBD; Leite TT; Parente Filho SLA; Rocha CVO; Daher EF
    Pathog Glob Health; 2017 May; 111(3):137-142. PubMed ID: 28353411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center.
    Akajagbor DS; Wilson SL; Shere-Wolfe KD; Dakum P; Charurat ME; Gilliam BL
    Clin Infect Dis; 2013 Nov; 57(9):1300-3. PubMed ID: 23840000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing the Population Pharmacokinetics of and Acute Kidney Injury Due to Polymyxin B in Chinese Patients with or without Renal Insufficiency.
    Wang P; Zhang Q; Zhu Z; Pei H; Feng M; Sun T; Yang J; Zhang X
    Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33168613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of polymyxin-B-associated acute kidney injury in 1-year mortality and renal function recovery.
    Gomes EC; Falci DR; Bergo P; Zavascki AP; Rigatto MH
    Int J Antimicrob Agents; 2018 Jul; 52(1):86-89. PubMed ID: 29501603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trough polymyxin B plasma concentration is an independent risk factor for its nephrotoxicity.
    Han L; Xu FM; Zhang XS; Zhang CH; Dai Y; Zhou ZY; Wang YX; Chen F; Shi DW; Lin GY; Yu XB
    Br J Clin Pharmacol; 2022 Mar; 88(3):1202-1210. PubMed ID: 34449094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe Infusion-Related Adverse Events and Renal Failure in Patients Receiving High-Dose Intravenous Polymyxin B.
    John JF; Falci DR; Rigatto MH; Oliveira RD; Kremer TG; Zavascki AP
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymyxin B and colistin-the economic burden of nephrotoxicity against multidrug resistant bacteria.
    Tuon FF; Rocha JL; Gasparetto J
    J Med Econ; 2019 Feb; 22(2):158-162. PubMed ID: 30466325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nephrotoxicity in Patients with or without Cystic Fibrosis Treated with Polymyxin B Compared to Colistin.
    Crass RL; Rutter WC; Burgess DR; Martin CA; Burgess DS
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and nephrotoxicity of polymyxin B in elderly patients with carbapenem resistant bacterial infection.
    Xia GL; Xu X; You XB; Wang X; Feng DD; Lei S; Jiang RL
    Ann Clin Microbiol Antimicrob; 2023 Nov; 22(1):101. PubMed ID: 37968642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.